During the corresponding time, Vivos Therapeutics Inc recorded a revenue increase by 65.69 % year on year, sequentially revenue grew by 1.86 %. While revenue at the Vivos Therapeutics Inc 's corporate clients
Vivos Therapeutics Inc's Comment on Sales, Marketing and Customers
The company serves a diverse customer base including dentists, sleep specialists, primary care physicians, medical specialists, chiropractors, nutritionists, physical therapists, and other healthcare providers treating dentofacial abnormalities affecting breathing and sleep. Its alliance marketing and distribution model targets sleep centers by offering alternatives to CPAP and surgery for patients with mild to severe obstructive sleep apnea (OSA). The company provides training through TVI to facilitate collaboration between healthcare professionals and dentists to improve clinical outcomes. It focuses on the medical profession as the primary source for OSA diagnosis and treatment, encompassing sleep centers, medical doctors, dentists, and durable medical equipment (DME) companies. The company operates within a large and growing global sleep apnea devices market, addressing millions of patients in the U.S., Canada, and Europe with sleep disorders and OSA. Data from the company’s VivoScore home sleep tests suggest a higher prevalence of OSA than some public estimates, with approximately 50% of tested patients diagnosed with OSA. Customers and markets referenced in company filings include Eli Lilly and ResMed.
Vivos Therapeutics Moves to Expand Reach with Acquisition of Largest Sleep Center Operator in Nevada Las Vegas, NV Vivos Therapeutics Inc. (NASDAQ: VVOS) has announced a definitive agreement to acquire the largest sleep center operator in Nevada, marking a significant strategic move for the company as it aims to consolidate its presence in the growing sleep disorder treatment market. This acquisition positions Vivos Therapeutics to enhance its service offerings and better serve the increasing number of individuals suffering from sleep-related issues.As of the writing of this article, Vivos Therapeutics shares are trading at $2.19, reflecting a performance that, while currently demonstrating resilience ag...
Breaking developments in the field of sleep disorder treatments have been announced, as Vivos Therapeutics’ flagship CARE Oral devices receive full approval for Medicare reimbursement. This marks a significant achievement as the company’s oral appliances are now the first to get endorsed by Medicare as treatment solutions for obstructive sleep apnea in adults, regardless of the severity of the condition.Sleep Apnea is a prevalent affliction within the medical world that significantly impacts the quality of life, in some instances, even posing a substantial threat to it. Obstructive Sleep Apnea (OSA) is characterized by recurrent episodes of partial or complete upper airway obstruction during sleep, leadi...
Vivos Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves a diverse customer base including dentists, sleep specialists, primary care physicians, medical specialists, chiropractors, nutritionists, physical therapists, and other healthcare providers treating dentofacial abnormalities affecting breathing and sleep. Its alliance marketing and distribution model targets sleep centers by offering alternatives to CPAP and surgery for patients with mild to severe obstructive sleep apnea (OSA). The company provides training through TVI to facilitate collaboration between healthcare professionals and dentists to improve clinical outcomes. It focuses on the medical profession as the primary source for OSA diagnosis and treatment, encompassing sleep centers, medical doctors, dentists, and durable medical equipment (DME) companies. The company operates within a large and growing global sleep apnea devices market, addressing millions of patients in the U.S., Canada, and Europe with sleep disorders and OSA. Data from the company’s VivoScore home sleep tests suggest a higher prevalence of OSA than some public estimates, with approximately 50% of tested patients diagnosed with OSA. Customers and markets referenced in company filings include Eli Lilly and ResMed.
Sources:
Vivos Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vivos Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vivos Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
54.24 %